Advertisement
Endocrinology

Susceptibility to Induced and Spontaneous Carcinogenesis Is Increased in Fatless A-ZIP/F-1 but not in Obese ob/ob Mice

Vitaly Ablamunits, Yehuda Cohen, Irina B. Brazee, Harold P. Gaetz, Charles Vinson and Simon Klebanov
DOI: 10.1158/0008-5472.CAN-05-4679 Published September 2006

Abstract

Obesity is typically associated with increased tumor susceptibility, whereas caloric restriction, a regimen resulting in leanness, inhibits carcinogenesis. The link between adiposity and malignancies suggests that adipose tissue may influence carcinogenesis. An adipose tissue hormone, leptin, could be procarcinogenic because it stimulates proliferation in various tissues and tumor cell lines. Leptin may contribute to the correlation between adiposity and malignancies as its levels are usually increased in obese subjects and reduced by caloric restriction. We hypothesized that leptin deficiency, despite obesity, would inhibit carcinogenesis in leptin-null ob/ob mice and tested this hypothesis in two models: (a) two-stage skin carcinogenesis initiated by 7,12-dimethylbenz(a)anthracene and promoted by phorbol 12-myristate 13-acetate (PMA) and (b) p53 deficiency. Contrary to a typical association between obesity and enhanced carcinogenesis, obese ob/ob mice developed induced skin papillomas and spontaneous p53-deficient malignancies, mostly lymphomas, similarly to their lean littermates. Surprisingly, lipodystrophic (ZIP) mice that had very little both adipose tissue and leptin were highly susceptible to carcinogenesis. Hyperphagia, hyperinsulinemia, and hyperglycemia are unlikely to have contributed significantly to the enhancement of carcinogenesis in ZIP mice because similarly hyperphagic, hyperinsulinemic, and hyperglycemic ob/ob mice had normal susceptibility to carcinogenesis. Our data suggest that, in contrast to a well-known correlation between obesity and cancer, the direct effect of adipose tissue may rather be protective. (Cancer Res 2006; 66(17): 8897-902)

  • Lipodystrophy
  • obesity
  • leptin
  • skin carcinogenesis
  • p53

Introduction

In humans, excessive body weight and obesity are linked to malignancies in numerous organs of gastrointestinal, reproductive, and hematopoietic systems ( 1– 4). Animal studies also find that diet-induced obesity ( 5– 9) and some forms of genetic obesity ( 10– 16) are associated with increased tumor susceptibility. A significant correlation between adiposity and cancer is suggestive of a direct influence of white adipose tissue on carcinogenesis. However, the mechanisms of how adipose tissue may affect carcinogenesis are poorly understood.

One possibility is that adipose tissue may affect carcinogenesis through adipokine secretion. Leptin may be a plausible candidate to mediate the effects of obesity and caloric restriction on carcinogenesis because it stimulates cellular proliferation in several tumor cell lines from esophagus and prostate ( 17), breast ( 17– 19), colon ( 20), and bone marrow ( 21). At the same time, leptin levels are usually increased in obesity in humans ( 22, 23) and animals ( 22, 24, 25).

To explore the effect of leptin deficiency on susceptibility to cancer, we chose the model of induced skin carcinogenesis because skin carcinogenesis is enhanced in obesity ( 11, 14), making it a likely candidate to be regulated by white adipose tissue. To ensure that the observed phenomena were not confined only to the skin, we also used p53-deficient mice, which die of spontaneous malignancies by 10 months ( 26).

To test whether leptin deficiency would reduce susceptibility to cancer, we used Lepob/Lepob (ob/ob) mice lacking leptin because of a mutation in the leptin gene ( 27). ob/ob mice are very obese; hence, potentially beneficial effects of the lack of leptin on carcinogenesis might be disguised in these mice by the negative effects of obesity. We therefore also tested the effect of leptin deficiency on carcinogenesis in lipodystrophic, A-ZIP/F-1 (ZIP) mice that almost completely lack leptin and white adipose tissue ( 28, 29).

Materials and Methods

Experimental animals and experimental groups. All mice were housed in a specific pathogen-free facility, fed ad libitum with LabDiet 5001 with 4% fat (PMI Nutrition International, Brentwood, MO), and maintained on a 14:10 light-dark cycle, with lights on at 7:00 a.m. and off at 9:00 p.m. Animal studies followed the guidelines of the American Association for Accreditation of Laboratory Animal Care and were approved by the Institutional Animal Care and Use Committee of St. Luke's-Roosevelt Hospital Center.

To study how leptin deficiency affects susceptibility to skin carcinogenesis, we used obese B6.V-Lepob/ob/J (here, ob/ob) and lean B6.V-Lep+/?/J (control) females purchased from The Jackson Laboratory (Bar Harbor, ME). To study how lipodystrophy affects susceptibility to skin carcinogenesis, we bred C57BL/6J (B6) females with FVB-Tg(A-ZIP/F-1)Vsn/J males, hemizygous by A-ZIP/F-1 transgene ( 28), and used lipodystrophic (B6 × FVB)F1-Tg(A-ZIP/F-1; here, ZIP) and normal (B6 × FVB) F1 (control) males. All mice were 8 to 11 weeks of age at the beginning of the study.

To study how leptin deficiency affects susceptibility to malignancies caused by p53 deficiency, we used obese Lepob/obTrp53tm1Tyj/tm1Tyj and lean Lep+/?Trp53tm1Tyj/tm1Tyj males on the B6 genetic background. These mice were obtained through several steps of breeding starting with B6.V-Lepob/+/J and B6.129S2-Trp53tm1Tyj/+/J ( 26) mice, obtained from The Jackson Laboratory. To study how lipodystrophy affects susceptibility to malignancies caused by p53 deficiency, we used lipodystrophic Tg(A-ZIP/F-1) Trp53tm1Tyj/tm1Tyj and their normal nontransgenic Trp53tm1Tyj/tm1Tyj littermate males. These mice were obtained through several steps of breeding starting with B6.129S2-Trp53tm1Tyj/+/J females and FVB-Tg(A-ZIP/F-1)1Vsn/J males. The genetic background of all experimental animals was the second backcross (N3) to the B6 strain. Additionally, some non-p53-null mice were studied (Trp53tm1Tyj/+ for the leptin deficiency study and Trp53+/+ for the lipodystrophy study) to assess the mortality from nonmalignancy causes.

Mice were genotyped according to the protocols provided at The Jackson Laboratory Web site. 6

Study of induced skin carcinogenesis. Because experimental animals differed in body size (e.g., ob/ob mice were larger than their lean control), we tried to ensure that the equal-area skin patches were subjected to carcinogenesis in all groups. All mice were shaved in the dorsal area near their tail and tattooed to mark a circular skin area of 1.5 cm in diameter. Two weeks later, 50 μg 7,12-dimethylbenz(a)anthracene (DMBA) dissolved in 200 μL acetone was applied to the marked skin patch. Another 2 weeks later, mice started to receive applications of phorbol 12-myristate 13-acetate (PMA), 4 μg in 50 μL acetone twice weekly for 25 weeks. Papillomas were observed weekly and those larger than 1 mm in diameter and present for 2 consecutive weeks were scored positive. At the end of the study, the mice were sacrificed and the papillomas were collected for histology.

Skin response to PMA was measured in naive ZIP and control mice. For that, four applications of 4 μg PMA in 50 μL acetone were applied over the period of 2 weeks and epidermal thickness was measured histologically on paraffin sections stained with H&E.

Study of spontaneous carcinogenesis in p53 deficiency. All experimental p53-null mice were weaned at 3 weeks of age and observed daily after weaning. Mice that had large tumors (>1 cm in diameter) or were clearly moribund were sacrificed. The rest were allowed to die naturally. All mice were necropsied and visible tumors, spleen, and liver were collected for histology.

Body weight and food consumption measurements. Body weights were measured at 6 months in the skin carcinogenesis study and at 15 weeks in the p53 deficiency study.

Food intake in the skin carcinogenesis study was measured in the same mice that were subjected to the carcinogenesis protocol. In the p53 deficiency study, food intake of p53-null mice might have been affected by occult malignancies. We therefore measured food intake in p53+/− (ob/ob groups) or p53+/+ (ZIP groups) littermates of the p53-null mice. Food intake for each group was measured daily in two to five separate cages, with three to five mice per cage, by weighing the food remaining in the food hopper. The measurements were done at 6 months of age.

Body composition measurements. Body composition was measured at 4 months of age, using dual energy X-ray absorptiometry (DEXA; Lunar PIXImus2, Lunar Corp., Madison, WI) under isoflurane anesthesia. Lean mass, fat mass, and percent fat were calculated using the software provided by the manufacturer.

Blood hormone and metabolite measurements. Blood samples were collected at 6 months of age in the skin carcinogenesis study and at 15 weeks of age in the p53 deficiency study. Blood glucose levels were measured by a FreeStyle blood glucose monitoring system (TheraSense, Inc., Alameda, CA). Plasma corticosterone levels were determined by a double-antibody corticosterone RIA 125I kit for rats and mice from MP Biomedicals LLC (Orangeburg, NY). Plasma adiponectin and insulin levels were assessed by mouse adiponectin and insulin RIA kits from LINCO Research, Inc. (St. Charles, MO). Plasma total insulin-like growth factor I (IGF-I) levels were measured by an IGF-I (direct) RIA from ALPCO Diagnostics (Salem, NH). Plasma leptin was determined by ELISA using Mouse Leptin DuoSet kit from R&D Systems, Inc. (Minneapolis, MN).

Statistics. Food intake, body weight, hormone, and metabolite levels and skin papilloma numbers were expressed as mean ± SE and analyzed by the two-tailed t test. Papilloma incidence was analyzed by the χ2 test. Survival analysis was done using the log-rank Kaplan-Meier estimation. Significance level was set at P < 0.05.

Results

Susceptibility to skin carcinogenesis is not increased in leptin-deficient ob/ob mice. ob/ob mice are extremely obese. Body composition measured by DEXA revealed a significant difference between ob/ob and lean B6 controls: lean mass, fat mass, and percent fat were 27.1 ± 0.5 g, 44.8 ± 1.2 g, and 62.3 ± 0.6% in ob/ob mice compared with 20.3 ± 0.6 g, 5.2 ± 0.4 g, and 20.2 ± 3.9% in lean controls, respectively.

To test whether leptin regulates susceptibility to skin carcinogenesis, leptin-deficient ob/ob mice were treated with DMBA and, beginning 2 weeks later, they were treated with PMA twice weekly for 25 weeks. The percentage of mice bearing papillomas and the average papilloma number are shown on Fig. 1A and B , respectively. Neither the incidence nor average tumor number differed between lean control and ob/ob mice. The incidence and the timing of onset in control B6 mice were comparable with those reported previously for this strain ( 30, 31).

Figure 1.
Figure 1.

Skin papilloma incidence and average number. Incidence (A) and the average number (B) of skin papillomas in ob/ob (n = 17) and lean control (n = 15) mice did not differ significantly at any time point. Incidence (C) and the average number (D) of skin papillomas in lipodystrophic ZIP (n = 17) mice were significantly higher (P < 0.05) than those in their normal littermates (n = 31) starting from week 9 of PMA treatment. Points, mean for each group; bars, SE (B and D).

Susceptibility to skin carcinogenesis is significantly increased in lipodystrophic ZIP mice. ob/ob mice lack leptin and are therefore obese. As obesity is linked to increased cancer susceptibility, including skin cancer ( 6, 11, 14), it could have disguised the beneficial effect of the lack of leptin in ob/ob mice. We therefore tested whether lipodystrophic ZIP mice ( 28, 29), for which we confirmed both leptin levels below 5% of those in controls ( Table 1 ) and the lack of visible adipose tissue, would be less susceptible to skin carcinogenesis than their normal littermates.

View this table:
Table 1.

Plasma hormone levels

We used the same carcinogenesis protocol as with ob/ob mice, a single application of DMBA followed by 25 weeks of PMA applications. The percentage of mice bearing papillomas and the average papilloma number are shown on Fig. 1C and D, respectively. Surprisingly, lipodystrophic mice developed tumors significantly earlier than control mice. They also developed significantly more tumors per animal. Representative papillomas in control and lipodystrophic mice after 25 weeks of PMA treatment are shown on Fig. 2A and B , respectively.

Figure 2.
Figure 2.

Skin papilloma gross appearance and morphology. Representative papillomas in control (A) and lipodystrophic ZIP (B) mice after 25 weeks of PMA treatment (grid divisions are 1 mm). H&E staining shows numerous venules with RBC in the lumen (arrows) scattered through a representative papilloma from a lipodystrophic ZIP mouse (C) and only few venules scattered in a representative papilloma from a control mouse (D). Con, control.

ZIP papillomas are better vascularized and epidermis of ZIP mice is more responsive to PMA. We tested whether ZIP mouse papillomas were histologically different from control mouse papillomas and found that they had a significantly higher capillary density ( Fig. 2C and D). This difference could explain a faster papilloma growth in ZIP mice.

To explain why lipodystrophic ZIP mice have high susceptibility to induced skin carcinogenesis, we hypothesized that their skin was more responsive to PMA treatment. Indeed, the growth response of the epidermis to four PMA applications over a 2-week period was much more pronounced in lipodystrophic ZIP than in normal control mice ( Fig. 3A-D ). This difference in the responsiveness to PMA could explain a significantly accelerated papilloma appearance in ZIP mice.

Figure 3.
Figure 3.

Epidermal response to PMA. All mice received four PMA applications over the course of 2 weeks. H&E-stained skin sections from control mice before (A) and after (B) PMA applications and from ZIP mice before (C) and after (D) PMA applications. The thickness of epidermis is similar in ZIP (C) and control (A) mice before the PMA treatment but is significantly increased in ZIP (D) compared with control (B) mice after the treatment.

Hormones that may affect susceptibility to carcinogenesis. As increased capillary density might have contributed to the accelerated papilloma growth in lipodystrophic mice, we measured the levels of adiponectin, a hormone, produced by white adipose tissue and suggested to be antiangiogenic ( 32). Adiponectin levels in lipodystrophic ZIP mice were below the detection limit (i.e., below 8% of those in control mice; Table 1), Adiponectin levels were also reduced in ob/ob mice but only to ∼50% of the control levels. Thus, a significant reduction in adiponectin might have contributed to the increase in capillary density in ZIP mice and, possibly, to accelerated papilloma growth.

Lipodystrophic mice, at 6 months of age, weighed ∼10 g more than normal control mice, 40.4 ± 0.6 and 31.4 ± 0.5 g (P < 0.001), respectively. The difference in lean mass was likely even larger because of the lack of adipose tissue in ZIP mice. Because IGF-I may both increase lean body mass and increase responsiveness to PMA ( 33, 34), we suspected that IGF-I might be elevated in ZIP mice. However, total IGF-I levels did not differ between control and ZIP mice, 243 ± 20 and 231 ± 15 ng/mL, respectively. Total IGF-I levels did not differ significantly between control (251 ± 10 ng/mL) and ob/ob (209 ± 15 ng/mL) mice either ( Table 1).

Glucocorticoids are potent inhibitors of skin carcinogenesis ( 35, 36) and corticosterone levels are highly elevated in ob/ob mice ( 37, 38). We therefore tested whether the difference in corticosterone levels might explain why ob/ob mice are much less susceptible to skin carcinogenesis than ZIP mice. Corticosterone levels were, however, similarly elevated in both ZIP and ob/ob mice by ∼3-fold over their respective controls [53 ± 8 and 165 ± 39 ng/mL in control and ZIP, respectively (n = 12-14; P < 0.05); 138 ± 26 and 421 ± 49 ng/mL in control and ob/ob, respectively (n = 5; P < 0.05; Table 1)]. Corticosterone, thus, does not seem to explain the difference in skin carcinogenesis between ob/ob and ZIP mice.

Leptin has a direct stimulatory effect on skin cells in vivo ( 39, 40) and in vitro ( 40– 42). We therefore measured leptin levels in ob/ob and ZIP mice to test whether some residual leptin could explain an increased skin tumor incidence in ZIP mice. As shown in Table 1, leptin levels in both ob/ob and ZIP mice were below the detection limit of our ELISA (i.e., <0.15 ng/mL, that is <5% of the respective control levels). Thus, residual leptin in ZIP is unlikely to explain a substantial difference in skin tumor incidence between ZIP and ob/ob mice.

Lipodystrophy shortens life span of carcinogenesis prone p53 knockout mice. A significant acceleration of carcinogenesis in the skin suggests that lipodystrophy may have a generalized promoting effect on malignancy. To test this hypothesis, we used mice deficient in the tumor suppressor p53 gene that spontaneously develop malignancies and die by 10 months of age ( 26, 43). We tested four groups of p53-null mice, ob/ob and their littermate controls and lipodystrophic ZIP and their littermate controls. Approximately 80% of mice in all groups died of lymphomas and thymomas. There was no significant difference between the groups in the variety and relative frequency of malignancies.

Longevity was not affected by obesity in leptin-deficient ob/ob mice ( Fig. 4A ). Life span of lipodystrophic ZIP mice was, however, significantly shorter (P < 0.05) than that of control mice, 136 ± 6 and 160 ± 10 days, respectively ( Fig. 4B). Survival of lipodystrophic and control mice was also different when analyzed using the log-rank Kaplan-Meier estimation (P < 0.05).

Figure 4.
Figure 4.

Survival of p53-deficient ob/ob and ZIP mice. Survival curves for p53-null obese ob/ob (n = 30) and normal lean control (n = 45) mice were almost indistinguishable (A). p53-null lipodystrophic ZIP mice (n = 24) were dying significantly earlier than their p53-null normal littermates (n = 25; B). Mortality of p53+/− ob/ob and control mice (A) and mortality of p53+/+ ZIP and control mice (B) were low and not significantly different from each other. One control mouse died at 306 days and is not shown on (A).

Hyperphagia and hyperglycemia are present not only in ZIP but also in ob/ob mice and therefore are likely not the reason for an increased susceptibility to carcinogenesis in ZIP mice. Because caloric restriction inhibits induced and spontaneous carcinogenesis ( 44– 47), we explored the possibility that hyperphagia and hyperglycemia characteristic of lipodystrophic ZIP mice ( 28) could be responsible for the enhanced susceptibility to carcinogenesis. In the two studies discussed above, on induced skin carcinogenesis and on spontaneous carcinogenesis in p53-deficient mice, ZIP mice were hyperphagic by 2.1- and 1.5-fold, respectively, and hyperglycemic by 2.7- and 1.6-fold, respectively, compared with their normal littermates ( Fig. 5 ). However, ob/ob mice were similarly hyperphagic, by 1.6- and 1.5-fold, and hyperglycemic, by 2.1- and 1.6-fold, compared with their normal littermates ( Fig. 5). As reported above, ob/ob, in contrast to ZIP mice, were not, however, more carcinogenesis susceptible than their normal littermates. Thus, probably, neither hyperphagia, nor hyperglycemia, nor hyperinsulinemia ( Table 1) per se contributed significantly to enhanced carcinogenesis in lipodystrophic ZIP mice.

Figure 5.
Figure 5.

Food intake and plasma glucose. In the skin carcinogenesis part of the study, food intake (A) and plasma glucose levels (B) were measured in the mutant, ob/ob, and ZIP mice and in their respective controls. The mutants were hyperphagic and hyperglycemic. *, P < 0.05. Likewise, the mutants were hyperphagic (C) and hyperglycemic (D) in the p53 deficiency part of the study (*, P < 0.05). Columns, mean; bars, SE.

Discussion

Skin carcinogenesis is enhanced in genetically obese Ay mice ( 11, 14) and in normal mice made obese by feeding a high fat diet ( 6). Here, we tested the hypothesis that leptin, which is increased in obesity ( 22– 25) and which has a direct stimulatory effect on skin cells in vivo ( 39, 40) and in vitro ( 40– 42), was responsible for the effects of obesity on the susceptibility to skin carcinogenesis. We found that leptin deficiency does not make ob/ob mice less susceptible than leptin-replete lean control mice. To test the possibility that a suppressive effect of the lack of leptin on skin carcinogenesis was disguised in ob/ob mice by their extreme obesity, we also tested whether skin carcinogenesis was suppressed in hypoleptinemic ZIP mice with very little white adipose tissue ( 28, 29). Contrary to our expectation, the lack of adipose tissue enhanced skin carcinogenesis.

When tested in another carcinogenesis model, p53 knockout mice, leptin deficiency again had no effect, whereas lipodystrophy significantly shortened life span of these malignancy-prone mice. Thus, lipodystrophy, in contrast to hypoleptinemic obesity, had a strong promoting effect on both induced skin and p53 deficiency carcinogenesis.

The enhancement of carcinogenesis in ZIP mice is unlikely due to some nonspecific effects of insulin resistance, diabetes, and hyperphagia as these phenomena are also present in ob/ob mice, which are not more susceptible to skin carcinogenesis than lean control mice.

Two hormones, IGF-I and corticosterone, known, respectively, to enhance ( 33, 34, 48) and suppress ( 35, 36, 49) carcinogenesis also cannot be responsible for the major difference between ob/ob and ZIP mice: IGF-I levels were not affected by either leptin deficiency or lipodystrophy and corticosterone levels were similarly elevated in both ob/ob and ZIP mice.

Most studies that find a positive relationship between adiposity and carcinogenesis have not been designed to test whether the relationship between obesity and cancer is causal ( 4, 7, 8, 10– 14, 16). In such studies, the adiposity was not an independent variable itself and the connection between adiposity and carcinogenesis, thus, might have arisen because both were regulated by the same underlying factor(s). In contrast, in the ZIP mouse, the primary effect causing lipodystrophy, the expression of a dominant-negative A-ZIP/F-1 transcription factor, is confined to preadipocytes/adipocytes themselves ( 28). Therefore, our finding that lipodystrophy enhances skin carcinogenesis unequivocally shows that white adipose tissue may indeed have a significant negative effect on carcinogenesis. To reconcile this apparently counterintuitive conclusion with numerous reports about positive correlation between adiposity and carcinogenesis, we propose that adipose tissue produces a carcinogenesis-suppressing factor, whose levels are decreased in obesity and elevated by caloric restriction.

One plausible candidate for such a factor is adiponectin. Its levels are decreased in obesity ( 50– 54) and are increased by caloric restriction ( 55, 56), a condition known to inhibit carcinogenesis ( 44– 47). Although adiponectin was only somewhat suppressed in ob/ob mice, it was undetectable in ZIP mice ( Table 1). Adiponectin is anticarcinogenic ( 32) and its absence in ZIP mice might have contributed to enhanced carcinogenesis. Its antiangiogenic activity ( 32) might have also been responsible for a significantly increased vascularization of papillomas in ZIP mice.

Interleukin-1 (IL-1) receptor antagonist, an anti-inflammatory protein secreted by adipose tissue ( 57), may be another adipokine with an anticarcinogenic effect ( 58, 59). However, the role of IL-1/IL-1 receptor/IL-1 receptor antagonist system in carcinogenesis has not been fully settled ( 60). Adipose tissue secretes a large number of adipokines ( 61) and their role in carcinogenesis will have to be addressed in future studies.

Our study shows that lipodystrophy enhances skin carcinogenesis and accelerates the development of lymphomas, thus establishing a potentially important role for adipose tissue as a modulator of carcinogenesis. One of the hormones mediating this effect of white adipose tissue may be adiponectin. Although the lack of an effect in ob/ob mice suggests that leptin reduction is not involved in mediating the inhibitory effect of caloric restriction on skin and hematopoietic carcinogenesis, the role of leptin in mediating the effects of caloric restriction and obesity on carcinogenesis in other tissues cannot be ruled out ( 62– 64). Finally, abnormal lipid metabolism in adipose tissue may have a direct effect on lipid metabolism in other tissues, leading to ectopic lipid accumulation and altered cancer susceptibility. Further studies of the endocrinology and metabolism of adipose tissue are required to clarify the nature of the relationship between obesity and carcinogenesis.

Acknowledgments

Grant support: NIH AG 19894 (S. Klebanov).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Footnotes

  • Received January 16, 2006.
  • Revision received May 16, 2006.
  • Accepted June 12, 2006.

References

  1. ↵
    Gerber M, Corpet D. Energy balance and cancers. Eur J Cancer Prev 1999; 8: 77–89.
    OpenUrlPubMed
  2. Brown P, Allen AR. Obesity linked to some forms of cancer. W V Med J 2002; 98: 271–2.
    OpenUrlPubMed
  3. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002; 3: 565–74.
    OpenUrlCrossRefPubMed
  4. ↵
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625–38.
    OpenUrlCrossRefPubMed
  5. ↵
    Jacobson EA, James KA, Frei JV, Carroll KK. Effects of dietary fat on long-term growth and mammary tumorigenesis in female Sprague-Dawley rats given a low dose of DMBA. Nutr Cancer 1988; 11: 221–7.
    OpenUrlPubMed
  6. ↵
    Birt DF, Pelling JC, Tibbels MG, Schweickert L. Acceleration of papilloma growth in mice fed high-fat diets during promotion of two-stage skin carcinogenesis. Nutr Cancer 1989; 12: 161–8.
    OpenUrlPubMed
  7. ↵
    Liu Z, Uesaka T, Watanabe H, Kato N. High fat diet enhances colonic cell proliferation and carcinogenesis in rats by elevating serum leptin. Int J Oncol 2001; 19: 1009–14.
    OpenUrlPubMed
  8. ↵
    Cleary MP, Grande JP, Maihle NJ. Effect of high fat diet on body weight and mammary tumor latency in MMTV-TGF-α mice. Int J Obes Relat Metab Disord 2004; 28: 956–62.
    OpenUrlCrossRefPubMed
  9. ↵
    de Assis S, Wang M, Goel S, Foxworth A, Helferich W, Hilakivi-Clarke L. Excessive weight gain during pregnancy increases carcinogen-induced mammary tumorigenesis in Sprague-Dawley and lean and obese Zucker Rats. J Nutr 2006; 136: 998–1004.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Heston WE, Vlahakis G. Influence of the Ay gene on mammary-gland tumors, hepatomas, and normal growth in mice. J Natl Cancer Inst 1961; 26: 969–83.
    OpenUrlPubMed
  11. ↵
    Vlahakis G, Heston WE. Increase of induced skin tumors in the mouse by the lethal yellow gene (Ay). J Natl Cancer Inst 1963; 31: 189–95.
    OpenUrlPubMed
  12. Wolff GL, Kodell RL, Cameron AM, Medina D. Accelerated appearance of chemically induced mammary carcinomas in obese yellow (Avy/A) (BALB/c X VY) F1 hybrid mice. J Toxicol Environ Health 1982; 10: 131–42.
    OpenUrlPubMed
  13. Becker FF. Progression of tumor histiotype during mouse hepatocarcinogenesis associated with the viable yellow (Avy) gene. Cancer Res 1986; 46: 2241–4.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Hansen LA, Malarkey DE, Wilkinson JE, Rosenberg M, Woychik RE, Tennant RW. Effect of the viable-yellow (A(vy)) agouti allele on skin tumorigenesis and humoral hypercalcemia in v-Ha-ras transgenic TGxAC mice. Carcinogenesis 1998; 19: 1837–45.
    OpenUrlAbstract/FREE Full Text
  15. Weber RV, Stein DE, Scholes J, Kral JG. Obesity potentiates AOM-induced colon cancer. Dig Dis Sci 2000; 45: 890–5.
    OpenUrlCrossRefPubMed
  16. ↵
    Cowey SL, Quast M, Belalcazar LM, et al. Abdominal obesity, insulin resistance, and colon carcinogenesis are increased in mutant mice lacking gastrin gene expression. Cancer 2005; 103: 2643–53.
    OpenUrlCrossRefPubMed
  17. ↵
    Somasundar P, Yu AK, Vona-Davis L, McFadden DW. Differential effects of leptin on cancer in vitro. J Surg Res 2003; 113: 50–5.
    OpenUrlCrossRefPubMed
  18. Hu X, Juneja SC, Maihle NJ, Cleary MP. Leptin-a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst 2002; 94: 1704–11.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Okumura M, Yamamoto M, Sakuma H, et al. Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-α and PPAR expression. Biochim Biophys Acta 2002; 1592: 107–16.
    OpenUrlPubMed
  20. ↵
    Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP. Leptin is a growth factor for colonic epithelial cells. Gastroenterology 2001; 121: 79–90.
    OpenUrlCrossRefPubMed
  21. ↵
    Konopleva M, Mikhail A, Estrov Z, et al. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood 1999; 93: 1668–76.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1: 1155–61.
    OpenUrlCrossRefPubMed
  23. ↵
    Luke AH, Rotimi CN, Cooper RS, et al. Leptin and body composition of Nigerians, Jamaicans, and U.S. blacks. Am J Clin Nutr 1998; 67: 391–6.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Frederich RC, Hamann A, Anderson S, Lollmann B, Lowell BB, Flier JS. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1995; 1: 1311–4.
    OpenUrlCrossRefPubMed
  25. ↵
    Van Heek M, Compton DS, France CF, et al. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 1997; 99: 385–90.
    OpenUrlCrossRefPubMed
  26. ↵
    Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 1992; 356: 215–21.
    OpenUrlCrossRefPubMed
  27. ↵
    Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425–32.
    OpenUrlCrossRefPubMed
  28. ↵
    Moitra J, Mason MM, Olive M, et al. Life without white fat: a transgenic mouse. Genes Dev 1998; 12: 3168–81.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Gavrilova O, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000; 105: 271–8.
    OpenUrlCrossRefPubMed
  30. ↵
    Iskander K, Paquet M, Brayton C, Jaiswal AK. Deficiency of NRH:quinone oxidoreductase 2 increases susceptibility to 7,12-dimethylbenz(a)anthracene and benzo(a)pyrene-induced skin carcinogenesis. Cancer Res 2004; 64: 5925–8.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Mustacich D, Wagner A, Williams R, et al. Increased skin carcinogenesis in a keratinocyte directed thioredoxin-1 transgenic mouse. Carcinogenesis 2004; 25: 1983–9.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Brakenhielm E, Veitonmaki N, Cao R, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004; 101: 2476–81.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Bol DK, Kiguchi K, Gimenez-Conti I, Rupp T, DiGiovanni J. Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice. Oncogene 1997; 14: 1725–34.
    OpenUrlCrossRefPubMed
  34. ↵
    DiGiovanni J, Bol DK, Wilker E, et al. Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion. Cancer Res 2000; 60: 1561–70.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Pashko LL, Schwartz AG. Reversal of food restriction-induced inhibition of mouse skin tumor promotion by adrenalectomy. Carcinogenesis 1992; 13: 1925–8.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Stewart JW, Koehler K, Jackson W, et al. Prevention of mouse skin tumor promotion by dietary energy restriction requires an intact adrenal gland and glucocorticoid supplementation restores inhibition. Carcinogenesis 2005; 26: 1077–84.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Dubuc PU, Mobley PW, Mahler RJ. Elevated glucocorticoids in obese-hyperglycemic mice. Horm Metab Res 1975; 7: 102.
    OpenUrl
  38. ↵
    Naeser P. Function of the adrenal cortex in obese-hyperglycemic mice (gene symbol ob). Diabetologia 1974; 10: 449–53.
    OpenUrlCrossRefPubMed
  39. ↵
    Ring BD, Scully S, Davis CR, et al. Systemically and topically administered leptin both accelerate wound healing in diabetic ob/ob mice. Endocrinology 2000; 141: 446–9.
    OpenUrlCrossRefPubMed
  40. ↵
    Frank S, Stallmeyer B, Kampfer H, Kolb N, Pfeilschifter J. Leptin enhances wound re-epithelialization and constitutes a direct function of leptin in skin repair. J Clin Invest 2000; 106: 501–9.
    OpenUrlCrossRefPubMed
  41. Stallmeyer B, Kampfer H, Podda M, Kaufmann R, Pfeilschifter J, Frank S. A novel keratinocyte mitogen: regulation of leptin and its functional receptor in skin repair. J Invest Dermatol 2001; 117: 98–105.
    OpenUrlCrossRefPubMed
  42. ↵
    Goren I, Pfeilschifter J, Frank S. Determination of leptin signaling pathways in human and murine keratinocytes. Biochem Biophys Res Commun 2003; 303: 1080–5.
    OpenUrlCrossRefPubMed
  43. ↵
    Hursting SD, Perkins SN, Phang JM. Calorie restriction delays spontaneous tumorigenesis in p53-knockout transgenic mice. Proc Natl Acad Sci U S A 1994; 91: 7036–40.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Weindruch R, Walford RL. The retardation of aging and disease by dietary restriction. Springfield (IL): Charles C Thomas; 1988.
  45. Kritchevsky D. Caloric restriction and experimental carcinogenesis. Toxicol Sci 1999; 52: 13–6.
    OpenUrlAbstract
  46. Thompson HJ, Zhu Z, Jiang W. Protection against cancer by energy restriction: all experimental approaches are not equal. J Nutr 2002; 132: 1047–9.
    OpenUrlFREE Full Text
  47. ↵
    Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med 2003; 54: 131–52.
    OpenUrlCrossRefPubMed
  48. ↵
    Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472–89.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 2004; 11 Suppl 1: S45–55.
    OpenUrlCrossRef
  50. ↵
    Makimura H, Mizuno TM, Bergen H, Mobbs CV. Adiponectin is stimulated by adrenalectomy in ob/ob mice and is highly correlated with resistin mRNA. Am J Physiol Endocrinol Metab 2002; 283: E1266–71.
    OpenUrlAbstract/FREE Full Text
  51. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79–83.
    OpenUrlCrossRefPubMed
  52. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930–5.
    OpenUrlCrossRefPubMed
  53. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity, and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46: 459–69.
    OpenUrlPubMed
  54. ↵
    Kwon K, Jung SH, Choi C, Park SH. Reciprocal association between visceral obesity and adiponectin: in healthy premenopausal women. Int J Cardiol 2005; 101: 385–90.
    OpenUrlCrossRefPubMed
  55. ↵
    Kopp HP, Krzyzanowska K, Mohlig M, Spranger J, Pfeiffer AF, Schernthaner G. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes (Lond) 2005; 29: 766–71.
    OpenUrlCrossRefPubMed
  56. ↵
    Combs TP, Berg AH, Rajala MW, et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 2003; 52: 268–76.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    Juge-Aubry CE, Somm E, Giusti V, et al. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 2003; 52: 1104–10.
    OpenUrlAbstract/FREE Full Text
  58. ↵
    La E, Rundhaug JE, Fischer SM. Role of intracellular interleukin-1 receptor antagonist in skin carcinogenesis. Mol Carcinog 2001; 30: 218–23.
    OpenUrlCrossRefPubMed
  59. ↵
    Li X, Eckard J, Shah R, Malluck C, Frenkel K. Interleukin-1α up-regulation in vivo by a potent carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) and control of DMBA-induced inflammatory responses. Cancer Res 2002; 62: 417–23.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    Murphy JE, Morales RE, Scott J, Kupper TS. IL-1 α, innate immunity, and skin carcinogenesis: the effect of constitutive expression of IL-1 α in epidermis on chemical carcinogenesis. J Immunol 2003; 170: 5697–703.
    OpenUrlAbstract/FREE Full Text
  61. ↵
    Trayhurn P. Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand 2005; 184: 285–93.
    OpenUrlCrossRefPubMed
  62. ↵
    Heston WE, Vlahakis G. Genetic obesity and neoplasia. J Natl Cancer Inst 1962; 29: 197–209.
    OpenUrlPubMed
  63. Vlahakis G, Heston WE. Relationship between recessive obesity and induced pulmonary tumors in mice. J Hered 1959; 50: 99–102.
    OpenUrlFREE Full Text
  64. ↵
    Cleary MP, Phillips FC, Getzin SC, et al. Genetically obese MMTV-TGF-α/Lep(ob)Lep(ob) female mice do not develop mammary tumors. Breast Cancer Res Treat 2003; 77: 205–15.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Cancer Research: 66 (17)
September 2006
Volume 66, Issue 17

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Email Article
Citation Tools
Susceptibility to Induced and Spontaneous Carcinogenesis Is Increased in Fatless A-ZIP/F-1 but not in Obese ob/ob Mice
Vitaly Ablamunits, Yehuda Cohen, Irina B. Brazee, Harold P. Gaetz, Charles Vinson and Simon Klebanov
Cancer Res September 1 2006 (66) (17) 8897-8902; DOI: 10.1158/0008-5472.CAN-05-4679
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement